Great Point Partners’s Arcellx ACLX Stock Holding History

Great Point Partners’s Portfolio ACLX Stock Details ACLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-100,000	Closed	-$8.35M	–	28
2024 Q3	$8.35M	Buy	+100,000	New	+$6.66M	2.46%	19

Other funds holding ACLX

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Great Point Partners's ACLX Position: Q3 2025 in Review

Great Point Partners sold out of Arcellx (ACLX) in Q3 2025, closing a stake of 100,000 shares — an estimated $6.58M sold.

Great Point Partners first reported a position in ACLX in Q1 2023 and held it in 9 quarters. The position peaked at $27.2M in Q2 2024. 209 funds tracked by Wall St. Rank hold ACLX as of Q3 2025.

Great Point Partners reported no remaining Arcellx position as of Q3 2025 after selling out during the quarter.
Great Point Partners sold 100,000 Arcellx shares in Q3 2025, an estimated $6.58M.
Great Point Partners first reported a position in Arcellx in Q1 2023 and held it in 9 quarters.
Great Point Partners's Arcellx position peaked at $27.2M in Q2 2024.
209 funds tracked by Wall St. Rank held Arcellx as of Q3 2025.

Based on Great Point Partners's 13F filing for Q3 2025, filed 14 Nov 2025.